Biocon Limited has informed Company Statement

Govt Defence OrderExport Order Hard CurrencyBusiness Updates View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.0%Reaction day

₹340.40

prior close

₹340.60

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.4%-1.7% vs market

Pharmaceuticals peers, median of 147sector-0.1%-2.0% vs sector

On the reaction day the stock moved 1.7 pts less than Nifty Midcap 150 and 2.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.1

10m

-1.2

15m

-1.6

30m

-1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.0-0.4-1.7-0.1-2.0

Next day

-2.8+0.2-3.0-0.3-2.5

-2.4+0.8-3.1-0.0-2.3

-1.6+1.0-2.6+0.2-1.8

-1.9+1.0-2.9+0.1-2.0

-1.4+1.6-3.0+0.5-1.9

-2.0+2.0-4.0-0.2-1.8

15d

+3.2+3.3-0.1+1.4+1.8

+3.3+2.6+0.7-2.8+6.1

+13.7+5.1+8.7+1.4+12.3

+5.4+2.9+2.4-1.0+6.4

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Government of Malaysia has agreed to extend its existing insulin supply contract with Biocon Biologics' Malaysian subsidiary, Biocon Sdn. Bhd., by an additional six months, from April 29, 2025 to October 28, 2025. The original 36-month contract was awarded in 2022 and was set to end in April 2025. Biocon Biologics has been supplying recombinant human insulin products manufactured at its Johor, Malaysia facility to Malaysia for nearly 10 years, with Duopharma Marketing Sdn. Bhd. as its commercial partner. A formal supplementary agreement will be executed subsequently between MoH, DMktg, and Biocon.

Likely market impact

This extension provides short-term revenue continuity for Biocon Biologics in the Malaysian market but is a brief bridge rather than a long-term win. Investors should watch for a fresh long-term tender, as the original three-year contract has now expired.